首页> 美国卫生研究院文献>Taylor Francis Open Select >Ethics of Clinical Science in a Public Health Emergency: Drug Discovery at the Bedside
【2h】

Ethics of Clinical Science in a Public Health Emergency: Drug Discovery at the Bedside

机译:突发公共卫生事件中的临床科学伦理学:床边的药物发现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clinical research under the usual regulatory constraints may be difficult or even impossible in a public health emergency. Regulators must seek to strike a good balance in granting as wide therapeutic access to new drugs as possible at the same time as gathering sound evidence of safety and effectiveness. To inform current policy, I reexamine the philosophical rationale for restricting new medicines to clinical trials, at any stage and for any population of patients (which resides in the precautionary principle), to show that its objective to protect public health, now or in the future, could soon be defeated in a pandemic. Providing wider therapeutic access and coordinating observations and natural experiments, including service delivery by cluster (wedged cluster trials), may provide such a balance. However, there are important questions of fairness to resolve before any such research can proceed.
机译:在公共卫生紧急情况下,在常规管制条件下进行临床研究可能很困难,甚至不可能。监管机构必须设法在寻求安全性和有效性的可靠证据的同时,尽可能多地获得新药的治疗途径之间取得良好的平衡。为了为当前政策提供依据,我重新审视了在任何阶段和针对任何人群(在预防原则之内)将新药限制在临床试验范围内的哲学原理,以表明其旨在保护现在或将来保护公众健康的目标。未来,很快就会在大流行中被击败。提供更广泛的治疗途径以及协调观察和自然实验,包括通过聚类提供服务(楔形聚类试验),可以实现这种平衡。但是,在进行任何此类研究之前,还有一些重要的公平问题需要解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号